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Abstract 
Chronic alcohol consumption can lead to an aberrant wound healing response of the liver, 
or hepatic fibrosis. Egr-1 is an essential regulator of many genes involved in the 
orchestration of tissue injury and repair, yet the implications of Egr-1 in different models 
of liver disease remain unclear. Previously, we demonstrated that carbon tetrachloride 
(CCl4)-induced hepatic fibrosis is enhanced in Egr-1 deficient mice. In this study, we 
investigated the role of Egr-1 in the attenuation of early markers of hepatic fibrosis using 
a model of ethanol-accelerated, CCl4-induced liver injury in wild-type and Egr-1 
deficient mice. Whereas Egr-1 mRNA was induced 100-fold in livers from wild-type 
mice 48h after CCl4 exposure, ethanol feeding reduced Egr-1 expression by 50 percent. 
Seventy-two hours after CCl4 exposure, hepatic mRNA accumulation of type I collagen 
and αSMA, markers of fibrogenesis expressed by activated hepatic stellate cells (HSC), 
were increased 22-fold and 20-fold, respectively, in both wild-type and Egr-1 -/- mice; 
levels of these transcripts were greater in ethanol-fed, Egr-1 -/- mice.  Consistently, plate-
induced activation of HSC from Egr-1 deficient mice was increased relative to HSC from 
wild-type mice. Previous use of an oxidant stress, antioxidant defense pathway array 
identified genes differentially expressed in ethanol-fed, Egr-1 -/- mice compared to 
ethanol-fed, wild-type mice after CCl4 exposure. We examined one of these genes, 
NAD(P)H dehydrogenase, quinone 1 (Nqo1), and found that Nqo1 mRNA and protein 
was reduced in Egr-1 -/-  mice relative to wild-type mice 72h after CCl4 exposure, and 
ethanol feeding exacerbated this reduction. Consistently, chromatin from livers of wild-
type, CCl4-treated mice confirmed association between Egr-1 and the Nqo1 promoter 
upon immunoprecipitation with an Egr-1 antibody. Although Egr-1 deficient mice did not 
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demonstrate inhibited oxidation of NADH after CCl4 via loss of Nqo1, β-lapachone-
mediated stimulation of Nqo1 activity suppressed CCl4-induced liver injury and 
fibrogenic changes. Collectively, these data support the hypothesis that Egr-1 attenuates 
early markers of hepatic fibrosis, and here we propose that Nqo1, a previously 
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Introduction 
Consequences of alcohol consumption remain a financial burden on United States 
healthcare. In 2006, an estimated 220 billion dollars in economic costs were spent due to 
excessive alcohol consumption [1]. Alcoholic liver disease (ALD), which includes a 
spectrum of liver pathologies ranging from fatty liver, or steatosis, to steatohepatitis, 
fibrosis, and cirrhosis, accounts for 1 in 10 deaths in adults aged 20-64 years and is 
increasing in prevalence [2]. While early stages of ALD can regress with abstinence from 
alcohol, cirrhosis, or end stage liver disease, can only be cured by liver transplantation. In 
an effort to discover earlier interventions and potential therapeutic targets, much research 
has been done to investigate the mechanisms of alcohol toxicity in the early stages of 
liver disease progression.  
Through a number of different mechanisms, alcohol acts to stimulate the build-up 
of triglycerides in the liver. Alcohol metabolism commonly occurs by the oxidation of 
ethanol to acetaldehyde and acetic acid by alcohol dehydrogenase (ADH) and 
acetaldehyde dehydrogenase (ALDH), respectively [3]. Under normal conditions, the 
balance between the oxidized and reduced form of nicotinamide adenine dinucleotide 
(NAD) is in favor of NAD+, the oxidized state; however, during ethanol metabolism 
increased levels of NADH accumulate intracellularly as NAD is reduced in both reactions 
[3]. The accumulation of NADH, an essential electron donor for many metabolic 
processes, stimulates the accumulation of free fatty acids (FA) through induction of FA 
synthesis and the simultaneous inhibition of β-oxidation and peroxisome proliferator-
activated receptor- α (PPARα) [4]. This ethanol-induced hyperlipidemia leads to hepatic 
steatosis, the essential first step in liver disease progression.	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While only 15-20% of patients with steatosis progress to fibrosis and cirrhosis [5], 
fatty liver increases susceptibility to the fibrogenic wound healing response and other 
advanced stages of liver disease. Through numerous pathways, FA accumulation can 
trigger the activation of hepatic stellate cells (HSC) to enhance their proliferation and 
extracellular matrix production and secretion—a hallmark of fibrosis.  It is thought that in 
addition to ethanol, fatty acids upregulate the expression of CYP2E1, and CYP2E1-
induced production of reactive oxygen species (ROS) leads to peroxidation of these fatty 
acids and mitochondrial damage [3]. This lipid peroxidation can then stimulate collagen 
synthesis and promote inflammation. Fatty liver has also been associated with increased 
periportal fibrogenesis through FA overactivation of the sympathetic nervous system and 
subsequent portal hypertension and signaling of HSC activation [6]. Additionally, 
research has shown that alcoholic fatty liver disease (AFLD) correlates with enhanced 
susceptibility of the liver to endotoxin-induced fibrogenic changes after chronic ethanol 
consumption due to disruption of intestinal permeability and increased pro-inflammatory 
cytokine production in macrophages and other infiltrating immune cells [4]. Tumor 
necrosis factor (TNF)-α, the major pro-inflammatory cytokine in ALD, increases the rate 
of FA synthesis and liver injury through activation of lipid-metabolism regulators such as 
sterol regulatory element-binding protein (SREBP)-1 and early growth response (Egr)-1 
[4, 7]. In fact, Laura Nagy’s group demonstrated that Egr-1 is required for the full 
activation of TNFα in response to LPS, and not only does Egr-1 contribute to increased 
LPS sensitivity, but it is also required for the development of chronic ethanol-induced 
liver injury [8].  
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Egr-1 is an immediate early response gene that encodes a zinc finger-containing 
transcription factor [9]. Induced by a variety of stimuli such as cytokines, growth factors, 
tissue damage and ROS, Egr-1 is a key mediator in multiple processes, including 
inflammation, angiogenesis, and extracellular matrix remodeling, which are involved in 
fibrosis [10, 11]. Regulation of genes such as vascular endothelial growth factor (VEGF) 
in angiogenesis and TNFα in inflammation support a positive role of Egr-1 in the 
regulation of the wound healing response. More importantly, control of the profibrotic 
cytokines transforming growth factor (TGF)-β, platelet-derived growth factor (PDGF), 
and fibroblast growth factor (FGF) suggest that Egr-1 is required for fibrosis in response 
to liver injury [12]. Indeed, Egr-1 has been shown to play a role in regulating fibrosis in 
various mouse models of human disease. For instance, Egr-1 was elevated in livers from 
mice after bile duct ligation, a model of cholestatic liver injury [13]. Consistently, Egr-1 
deficiency protected against bleomycin-induced dermal and lung fibrosis as well as 
LPS/galactosamine-induced liver injury [14-16]. In contrast, Egr-1 deficiency worsened 
fibrosis in a model of xenobiotic-induced cholestasis in mice independent of changes in 
injury or inflammation [17]. Similarly, recent studies have shown that carbon 
tetrachloride (CCl4)-induced hepatic fibrosis was enhanced, not attenuated, in mice 
lacking Egr-1 [18, 19]. In consequence, the function of Egr-1 in fibrosis remains poorly 
understood, and further investigation into the effects of Egr-1 deficiency on hepatic 
fibrosis could help to better understand how Egr-1 may be used as a potential target for 
the development of anti-fibrotic interventions.    
In this study, we hypothesized that the loss of Egr-1 exacerbates CCl4-induced 
liver injury, which subsequently contributes to the progression to fibrosis. Making use of 
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Egr-1 deficient mice, we investigated whether the loss of Egr-1 would contribute to 
injury, steatosis, and the appearance of early markers of fibrosis using a model of 
moderate ethanol feeding to accelerate CCl4-induced fibrogenesis paralleling the 
acceleration of fibrosis by ethanol in wild-type mice shown previously by Roychowdhury 
et. al [20]. While Egr-1 deficiency had no effect on CCl4-mediated hepatic injury, 
steatosis and expression of early fibrosis markers was increased in Egr-1 -/- mice and 
ethanol feeding worsened this effect demonstrating a protective role of Egr-1 in the 
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Our overall hypothesis was that Egr-1 contributes to the attenuation of hepatic fibrosis, 
and this was tested as defined briefly in the following specific aims. 
Specific Aim 1: Determine the effects of Egr-1 on the induction of early markers of 
fibrosis. Based on previous work illustrating that Egr-1 is a negative regulator of chronic 
CCl4-induced hepatic fibrosis and the oval cell response [18], we tested the hypothesis 
that Egr-1 attenuates, not exacerbates, hepatic fibrogenesis. We tested this hypothesis 
using a model of ethanol-accelerated, CCl4-induced liver injury to stimulate fibrogenesis 
in wild-type and Egr-1 deficient mice. Consequently, we measured changes in liver injury 
by ALT and AST; changes in steatosis by hepatic triglyceride content, and fibrogenic 
changes as measured by transcript and protein levels of common markers of fibrogenesis.   
Specific Aim 2: Identify gene targets of Egr-1 that may contribute to the Egr-1-
mediated effects on fibrogenesis. Reactive oxygen species (ROS) are a product of both 
ethanol metabolism and CYP2E1-mediated bioactivation of CCl4. Since Egr-1 is rapidly 
and transiently induced in the presence of ROS and oxidative damage, we tested the 
hypothesis that Egr-1 regulates antioxidant genes, which may play an essential role in the 
attenuation of hepatic fibrosis. To the test this hypothesis, we followed up on the results 
of an SA Biosciences Oxidant Stress, Antioxidant Defense Pathway array with real-time 
PCR and Western blot analysis. Chromatin immunoprecipitation was subsequently 
performed to investigate the relationship between Egr-1 and a suspected gene target, 
NAD(P)H dehydrogenase, quinone 1 (Nqo1). 
Specific Aim 3: Define mechanisms by which Egr-1 exerts inhibitory effects on liver 
disease progression. To determine the mechanism by which Egr-1-mediated induction of 
Nqo1 protects against ethanol-fed, CCl4-induced liver injury, we explored the different 
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functions of Nqo1. To investigate effects of Egr-1 deficiency on oxidative damage, we 
quantified oxidative stress by immunohistochemistry of 4-hydroxynonenal (4-HNE), 
glutathione depletion assay, and assay of cellular total antioxidant capacity in wild-type 
and Egr-1 -/- mice after ethanol feeding and CCl4 exposure. We also performed 
histological quantification of abnormal mitotic figures and measurement of cellular 
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Materials and Methods 
 
Antibodies: 4-HNE (Alpha Diagnostic, San Antonio, TX), Nqo1 and α-smooth muscle 
actin (αSMA) (clone 1A4) (Sigma-Aldrich, St. Louis, MO), Egr-1 (clone 15F7) and 
GAPDH (clone 14C10) (Cell Signaling, Danvers, MA), and RNA polymerase II 
(Millipore, Darmstadt, Germany).   
Animals and Experimental Design 
All experiments were conducted with the approval of the Institutional Animal Care and 
Use Committee at the University of Kansas Medical Center. Mice deficient in Egr-1 were 
bred from male and female heterozygotes (Egr-1 +/-) on a C57BL/6 Taconic 
background; wild-type control mice were littermates of Egr-1 -/- mice. Ten to 12-week-
old female Egr-1 +/+ and Egr-1 -/- mice were housed in ventilated cages on a 10/14h 
light and dark cycle in 50% humidity. Animals were grouped 2 per cage, and those on 
control diet were paired to ethanol-fed animals to equalize caloric intake between groups 
for the following experiment.  
Model of Ethanol-accelerated, CCl4-induced fibrogenesis: Using methods previously 
described [20], mice were acclimatized to a liquid diet for 2 days, and subsequently fed 
increasing concentrations of ethanol (1 to 2% v/v) for 2 days each. Lieber-DeCarli high 
fat ethanol and control diets were obtained from Dyets (Bethlehem, PA). After two days 
of 2% ethanol feeding, mice were injected with CCl4 (0.4mg/g bw, diluted 1:3 in olive 
oil) or olive oil alone for control [21]. Mice continued on pair and ethanol-containing 
diets until euthanized 48 and 72hr after CCl4 injection. Mice were euthanized 12hr post 
CCl4 for 4-HNE immunohistochemistry.  
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β-Lapachone administration: β-Lapachone (β-L) purchased from Abcam (Cambridge, 
MA) was dissolved in DMSO (8mg/mL) and injected i.p. at 20mg/kg in 100mg/kg of 
hydroxypropyl-β-cyclodextrin (CTD Holdings, Inc., Alachua, FL) to increase 
bioavailability and solubility [22]. The first β-L injection occurred 12hr prior to CCl4 
administration, and was given once daily until mice were euthanized 72hr after CCl4 
exposure.  
For euthanasia, mice were anesthetized with a cocktail of 107.2mg/kg ketamine, 
4.29mg/kg xylazine, and 3.55mg/kg acepromazine; blood was taken from the vena cava 
and collected into EDTA-containing tubes supplemented with aprotinin to obtain plasma. 
The liver was excised, sectioned, snap frozen in liquid nitrogen, and stored at -80°C. 
Separate liver pieces were formalin-fixed and paraffin-embedded for further histological 
analysis, or saved in RNAlater® solution (Life Technologies, Grand Island, NY) for 
RNA isolation and cDNA synthesis.  
Hepatic stellate cell (HSC) isolation: Here, animals were euthanized by cervical 
dislocation. Livers were harvested and placed into 25mL of Hanks balanced salt solution 
(HBBS) deficient in Ca+ and Mg+ (Gibco®, Life Technologies). In a culture hood, livers 
were washed 2-3 times in HBBS deficient in Ca+ and Mg+ to remove blood. After the 
final wash, livers were minced and transferred to individual 250mL Nalgene flasks with 
10mL of enzyme solution (3.75mg/mL pronase, 0.5mg/mL collagenase, and 0.1mg/mL 
Dnase I in HBBS deficient in Ca+ and Mg+). Flasks were then incubated in a water bath 
at 37°C, shaken at 100rpm. Digests were poured through a Cellector (#30 metal mesh 
insert, Bellco Glass, Vineland, NJ) into 50mL centrifuge tubes. Final volumes were 
brought to 50mL with HBBS deficient in Ca+ and Mg+ and tubes were centrifuged at 50 x 
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g for 5min at 4°C to pellet hepatocytes and red blood cells. Supernatants containing non-
parenchymal cells (NPC) were transferred to new 50mL centrifuge tubes and final 
volumes were brought to 50mL with HBBS deficient in Ca+ and Mg+. Tubes were then 
centrifuged at 1,000 x g for 6min at 4°C to pellet remaining NPC. All but 5mL of 
supernatant was removed, and NPC pellets were resuspended in the remaining 
supernatant. To each tube, 30mL of HBBS deficient in Ca+ and Mg+ was added with 
400µL of Dnase I and centrifugation at 1,000 x g for 6min at 4°C was performed. After 
removal of supernatants, pellets were resuspended in 2.5mL of HBBS deficient in Ca+ 
and Mg+ and 2mL of 3g/L Ultra Fatty Acid Free BSA (Roche) was added. Samples were 
transferred to 15mL centrifuge tubes, and 4mL of 28.7% Histodenz (Sigma-Aldrich) in 
HBBS deficient in NaCl was added. Subsequently, 3mL of HBBS with 3g/L BSA was 
added slowly to maintain a sharp interface between the sample and the HBBS. Following 
centrifugation at 2,500 x g for 17min at 4°C, the opaque interface containing HSC was 
transferred to pre-chilled 15mL centrifuge tubes containing 5mL of Dulbeco’s Modified 
Eagle’s medium (DMEM) with 20% fetal bovine serum (FBS). Additional centrifugation 
was performed at 1,000 x g for 5min at 4°C, and supernatants were discarded. Pellets 
were resuspended in 1mL DMEM and 20% FBS, and 10µL of resultant cells were mixed 
with 40µL of trypan blue for cell counting. Cells were diluted for plating at 
250,000cells/cm2, and 24 hours later, medium was changed to eliminate non-adherent 
cells. Cells were harvested 5, 7, and 10 days after plating for subsequent RNA and 
protein analysis.  
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RNA Isolation and PCR 
RNA was isolated from liver using the Qiagen RNeasy Mini Kit or from HSC with the 
Qiagen RNeasy Micro Kit (Valencia, CA). Reverse transcription and cDNA synthesis 
was performed with the use of the RETROscript® kit from Ambion, Inc (Grand Island, 
NY). Real-time polymerase chain reaction (real-time PCR) was performed using a Real-
time PCR CFX384 plate reader (BioRad, Hercules, CA) with primers specific to genes of 
interest; 18S was used for normalization. All primers were obtained from Integrated 
DNA Technologies (IDT) (Table 1). Data collected was analyzed using the Livak method 
where the resultant Ct value represented the cycle at which a threshold was reached per 
gene of interest. Calculation of ΔCt was performed by subtracting the Ct for 18S from the 
Ct for the gene of interest, and ΔΔCt was calculated by subtracting the ΔCt of each 
treatment group from the ΔCt of the control group. Fold changes were calculated as 2-
ΔΔCt. 
Table 1. List of primer sequences used for real-time PCR analysis. 
Gene 
Name 
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Western Blotting 
Protein lysates were made from liver pieces between 50-100mg. Liver pieces were 
homogenized in 1X RIPA buffer with added proteinase inhibitors in pre-filled bead 
homogenization tubes (Wisbiomed, San Mateo, CA) at 4m/s for 45sec in a bead 
homogenizer (Fast Prep 24, MP Biomedicals, Solon, OH). After centrifugation at 21,000 
x g for 15min at 4°C, supernatants were diluted 1:30 in water and the Pierce® BCA assay 
(Thermo Scientific, Waltham, MA) was used to determine protein concentrations. Forty 
micrograms of protein was loaded onto a 10% polyacrylamide gel and electrophoresed at 
125V for 85 minutes.  Protein was transferred to a PVDF membrane at 0.04A for 75 
minutes. Membranes were blocked in 5% BSA in Tris-buffered saline with 0.1% Tween 
20 (TBST) for an hour at room temperature, then incubated with primary antibody 
overnight at 4°C on an orbital shaker. Primary antibodies were diluted in 1% BSA in 
TBST and 0.02% sodium azide at 1:5,000 for anti-Nqo1, 1:2,000 for anti-Hsp47, and 
1:1,000 for anti-αSMA. Secondary antibody incubation was done at 1: 20,000 in 3% 
BSA in TBST for an hour at room temperature. GAPDH was used as the loading control 
for all proteins of interest. Immunodetection was done by chemiluminescence using 
Amersham ECL™ Western blotting kit (GE Healthcare).  
HNE Immunohistochemistry 
Formalin-fixed, paraffin-embedded tissue was deparaffinized and stained for 4-HNE 
using a protocol outlined by Gavin Arteel [23]. The primary antibody was diluted 1:250 
in 1% BSA in phosphate-buffered saline with 5% Tween 20 (PBST), and 
immunohistochemical detection was done using the Dako EnVision Kit (Carpinteria, 
CA).  
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Plasma ALT/AST Activity Assay 
ALT and AST assays were performed on isolated plasma samples with kits from Sekisui 
Diagnostics (Lexington, MA). Plasma samples were diluted in saline based on previous 
data collected in the lab. In a UV-invisible 96-well plate, 10µL of each diluted sample 
was added in duplicate (5µL for AST activity assay). Subsequently, 90µL of ALT reagent 
(1 part reagent 1 to 4 parts reagent 2) was added to each well (100µL of AST reagent), 
and absorbance readings were taken every 30sec over 5min at 340nm.  
Hepatic Triglyceride Measurement 
Total hepatic triglyceride levels were measured using reagents purchased from Pointe 
Scientific, Inc (Canton, MI). Liver pieces between 75-95mg were digested in 3M KOH in 
65% ethanol at 70°C for an hour. Following 24hr incubation at room temperature, sample 
volumes were brought to 500µL with 2M Tris-HCl, pH 7.5. Samples were then diluted 
1:5 in separate tubes containing 400µL of 2M Tris-HCl, pH 7.5, and 10µL of diluted 
sample was added to 1mL of prewarmed (37°C for 5min) GPO liquid reagent. Different 
volumes (0, 0.63, 1.25, 2.5, 3.75, 5, 7.5, 10, 20, and 40µL) of GPO standard reagent were 
added to prewarmed 1mL tubes of GPO liquid reagent to create a standard curve. After a 
second incubation at 37°C for 5min, 200µL of each standard and sample was added to a 
96-well plate in duplicate. Absorbances were read at a wavelength of 500nm and adjusted 
for the absorbance of water, which was used as a blank. Total hepatic triglyceride content 
was calculated using the linear equation generated by the standard curve.  
CYP2E1 Activity Assay 
Using methods modified from those described previsouly [24], samples were 
homogenized in ice-cold PBS and centrifuged for 15min at 9,000 x g at 4°C. 
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Supernatants were ultracentrifuged at 105,000 x g for an hour at 4°C to isolate 
microsomal fractions. Microsomes were diluted in 0.15M KCl and assayed in a 100µL 
reaction mixture of 10mM p-nitrophenol, phosphate buffer, NADPH, and 100µg of 
protein. Protein normalization was determined by BCA assay. After an hour, the reaction 
was stopped with 20% TCA, and CYP2E1 activity, measured in 10N NaOH, was read at 
a wavelength of 510nm. 
Nqo1 Activity Assay 
Nqo1 activity was determined using a previously described protocol [25]. Briefly, liver 
samples were homogenized in a sample buffer of 25mM Tris-HCl, 250mM sucrose, and 
1µM FAD, pH 7.4. Following centrifugation at 10,000 x g for 5min at 4°C, supernatants 
were ultracentrifuged at 120,000 x g for an hour at 4°C to collect cytosolic fractions. In a 
reaction mixture of 500µM NADPH, 40µM DCPIP, 50mM Tris-HCl, and 20µg of 
protein Nqo1 activity was assayed over 5 minutes at 27°C at a wavelength of 600nm.  
Chromatin Immunoprecipitation 
To investigate the interaction between Egr-1 and the Nqo1 promoter, around 200mg of 
mouse liver was homogenized in 1mL of cell lysis buffer (10mM Tris-HCl, 10mM NaCl, 
3mM MgCl2, 0.5% NP-40) containing protease inhibitors (10µL/mL). Crosslinks were 
formed between protein and DNA using 25µL of 10% buffered formalin phosphate with 
rotation at room temperature for 30 minutes. Glycine (100µL), with an additional 5 
minutes of rotation, was used to stop crosslinking. After centrifugation at 2,000 x g for 2 
minutes at 4°C, nuclei were lysed with resuspension of resultant pellet in 1mL of nuclear 
lysis buffer (0.2% SDS, 5mM EDTA, 50mM Tris-HCl) containing protease inhibitors. 
Chromatin was then sheared to 200-1000bp by sonication, and sonication efficiency was 
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determined by gel electrophoresis. Subsequently, 50µg of chromatin was pre-cleared for 
an hour with rotation at 4°C in Invitrogen Dynabeads, then immunoprecipitated overnight 
with Egr-1 antibody, RNA Polymerase II antibody as a positive control, or no antibody as 
a negative control. Following overnight incubation, washed Dynabeads were added to 
each sample to isolate antibody-bound chromatin, and beads were subsequently washed 
in a ChIP low-salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 50mM Hepes, 
150mM NaCl), ChIP high-salt buffer (same as low-salt buffer, but with 500mM NaCl), 
ChIP LiCl buffer (0.25mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate, 1mM EDTA, 
10mM Tris-HCl), and TE buffer (10mM Tris-HCl, 1mM EDTA), consecutively. 
Chromatin was then eluted and crosslinks reversed by incubation overnight at 65°C. 
DNA was then purified via phenol:chloroform extraction and analyzed by real-time PCR 
using primers specific to the Nqo1 promoter.  
Glutathione (GSH) Measurement 
GSH levels were measured using a previously described protocol [26], in which frozen 
liver sections were homogenized in 3% sulfosalicylic acid with 0.1mM EDTA. To 
determine total glutathione, homogenates were diluted in 0.01N HCl, centrifuged at 
18,000 x g for 4min at 4°C, and further diluted in potassium phosphate buffer (KPP). To 
determine glutathione disulfide (GSSG), homogenates were diluted in N-ethylmaleimide 
(NEM) and KPP. NEM served to trap GSH to isolate GSSG in solution. Absorbances 
were measured in a test solution of 5,5’-Dithio-bis(2-nitrobenzoic acid) (DTNB) at a 
wavelength of 412nm.  
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Total Antioxidant Capacity Assay 
Total antioxidant capacity was quantified with the use of Cell BioLab’s Oxiselect™ TAC 
assay kit per manufacturer-provided protocol. Liver samples were homogenized in cold 
PBS with the use of an automated bead homgenizer (Fast Prep 24) and centrifuged at 
10,000 x g for 10min at 4°C. In a 96-well microtiter plate, 20µL of freshly made diluted 
uric acid standard and supernatant from each sample was added in duplicate. To each 
well, 180µL of 1X Reaction Buffer was added using a multichannel pipette and mixed 
thoroughly. Following an initial absorbance read at 490nm, the reaction was initiated 
with the addition of 50µL of 1X Copper Ion Reagent and incubated for 5min on an 
orbital shaker. The reaction was terminated upon addition of 50µL of 1X Stop Solution 
and a final absorbance read was again measured at 490nm.  
NAD+/NADH Quantification 
With the use of an NAD+/NADH quantification colorimetric kit obtained from BioVision 
(Milpitas, CA), samples were assayed per manufacturers instructions. Liver was 
homogenized in 400µL of NADH/NAD extraction buffer. Following centrifugation at 
18,400 x g for 5min, half the supernatant was transferred to a new tube and incubated at 
60°C for 30min to decompose NAD. Samples containing total NAD and NADH alone 
were diluted in NADH/NAD extraction buffer and assayed in a mixture of NADH 
cycling buffer, NADH cycling enzyme mix, and NADH developer. Absorbances were 
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Statistical Analysis 
Densitometry of immunoblots and quantification of immunohistochemistry was done 
with the use of ImageJ [27]. Statistical analysis was performed by ANOVA post hoc 
analysis using Tukey’s adjustment for multiple measures on SAS. For CYP2E1 activity 
and β-Lapachone experiments, the student’s t-test was used for analysis. All data are 
represented as the mean ± the standard error of the mean (SEM). For all instances, N ≥ 4 
mice per experimental group where * denotes different than wild-type and ** denotes 
different in Egr-1 -/- between pair and ethanol-fed knockouts and ethanol-fed wild-type 
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Results 
Ethanol feeding reduces Egr-1 and exacerbates the appearance of early markers of 
fibrosis. Egr-1 is implicated in the pathogenesis of fibrosis in models of lung fibrosis and 
scleroderma [15]; however, it remains unclear what happens to Egr-1 after moderate 
ethanol feeding and CCl4 exposure and how its expression affects the progression of 
hepatic fibrosis. We found that 48h after a single CCl4 injection, which initiates the 
appearance of hepatic fibrosis, there was a 50% reduction in the transcript levels of Egr-1 
with ethanol feeding (Fig. 1A). By 72h, Egr-1 mRNA levels in both pair and ethanol-fed 
mice returned nearly to baseline. Interestingly, Egr-1 protein was stabilized up to 72h 
after CCl4 injection, but ethanol feeding inhibited this effect.  
To investigate the effects of Egr-1 deficiency on hepatic fibrosis, we examined 
the expression of Col1a1 and αSMA in whole liver from Egr-1 +/+ and Egr-1 -/- mice 
72h after CCl4 exposure (Fig. 2).  Hepatic stellate cells (HSC), the main cell type 
responsible for hepatic fibrosis, excessively deposit type I collagen and express αSMA 
during progression of the disease. To date, these genes are commonly used as markers of 
HSC activation. In our studies, we found that not only was Col1a1 and αSMA mRNA 
increased 72h after CCl4, but we also found that the loss of Egr-1 exacerbated this 
induction (Fig. 2A). Although the data are not significant for Col1a1, ethanol feeding 
further heightened the induction of αSMA mRNA after CCl4 (Fig. 2A). Similarly, 
immunoblotting for αSMA demonstrated the same pattern of expression (Fig. 2B). We 
also examined transcript levels of these genes within HSC isolated from wild-type and 
Egr-1 -/- mice, and consistently discovered that as these cells spontaneously activate in 
culture over time there was an induction of Col1a1 and αSMA in wild-type HSC that was 
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enhanced in Egr-1 -/- HSC. Together, these data demonstrate an accelerated profibrotic 
phenotype in CCl4 exposed, Egr-1 -/- mice that is worsened with ethanol feeding, and this 
suggests that Egr-1 attenuates, not exacerbates, fibrogenic changes in the liver after 
















Figure 1. Ethanol feeding reduces Egr-1 mRNA and protein levels. (A) Real-time 
PCR was performed on livers from pair and ethanol-fed mice 48 and 72h after CCl4 to 
measure transcript levels of Egr-1. (B) Egr-1 protein content was determined by Western 
blot from pooled mouse liver samples. Densitometric analysis of Western blot data was 
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Figure 2. Ethanol feeding increases hepatic accumulation of fibrotic markers from 
CCl4-treated, Egr-1-deficient mice. Real-time PCR was used to determine hepatic (A) 
αSMA and Col1a1 transcript level. (B) Western blotting on pooled liver homogenates 
was used to determine αSMA protein quantity; GAPDH was used as a loading control. 
Consistently, real-Time PCR shows enhanced expression of fibrosis markers in hepatic 
stellate cells (C).  
 
 
Egr-1 deficiency and ethanol feeding delay recovery from CCl4-induced steatosis, 
independent of liver injury. As the first in a spectrum of liver pathologies that arise 
from chronic alcohol consumption, steatosis can predispose patients to liver disease 
progression. Since our data suggest that the loss of Egr-1 increases fibrogenesis in the 
liver after CCl4 and ethanol feeding, we hypothesized that Egr-1 deficiency would also 
lead to an increase in steatosis. First, in an effort to rule out the possibility that the 
accelerated profibrotic phenotype seen in Egr-1 -/- mice was due to enhanced liver injury, 
we measured the severity of liver injury after CCl4 exposure by plasma alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) activities (Fig. 3A). At the 
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time of peak injury following CCl4 (48h), markers of liver injury showed no difference 
between genotypes or diets (Fig. 3A).   
Second, we examined steatosis by measuring hepatic triglyceride levels and found 
that steatosis was increased in both genotypes after CCl4 (Fig. 3B); however, triglycerides 
remained elevated in Egr-1 -/- mice while this level was reduced to baseline in wild-type 
mice at 72h. Ethanol feeding further increased hepatic triglyceride accumulation.  
Lastly, similar to Roychowdhury et. al [20], we sought to confirm that moderate 
ethanol used in this model did not increase the bioactivation of CCl4. Chronic ethanol 
consumption induces the cytochrome P450 enzyme CYP2E1. CYP2E1 contributes to the 
metabolism of ethanol, and is the same enzyme that metabolizes the bioactivation of 
CCl4. Therefore, high concentrations of ethanol can induce CYP2E1, and thus increase 
the bioactivation of CCl4 into its reactive metabolites, accelerating fibrogenesis. 
However, the use of 2% ethanol in this animal model showed no differences in CYP2E1 
activity between wild-type and Egr-1 -/- and pair and ethanol-fed mice (Fig. 3C). This 
suggests that the enhanced fibrogenic changes seen in the Egr-1 -/- mice are independent 
of differences in liver injury and CYP2E1-mediated bioactivation of CCl4. Collectively, 
these data support the hypothesis that in addition to attenuating fibrogenic changes in the 



























Figure 3. Enhanced fibrogenic changes in Egr-1 -/- mice are independent of 
increased liver injury and CCl4 bioactivation. Plasma ALT and AST activities (A) and 
hepatic triglyceride (B) were determined 48 and 72h after CCl4. These data are 




Loss of Egr-1 inhibits the induction of Nqo1 after ethanol feeding and CCl4 
exposure. Egr-1 is a redox-sensitive transcription factor that is highly inducible by a 
variety of stimuli including cellular oxidative stress [28]. In CYP2E1-mediated 
metabolism of ethanol, the use of oxygen to metabolize alcohol can lead to the generation 
of reactive oxygen species (ROS). CYP2E1 can also catalyze the formation of an ethanol-
derived free radical, which also contributes to oxidative damage [29]. Similarly, 
metabolism of CCl4 by CYP2E1 leads to the formation of reactive metabolites, such as 
CCl3• and CCl3OO•, which can bind to cellular macromolecules, including lipids, 
leading to lipid peroxidation and the formation of ROS. Therefore, we sought to test the 
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hypothesis that Egr-1 attenuates hepatic fibrosis through augmentation of antioxidants, 
such that the loss of Egr-1 leads to a loss in antioxidant expression and increased 
fibrogenesis. An SA Biosciences Oxidant Stress, Antioxidant Defense Pathway array was 
performed on liver from ethanol-fed, wild-type and Egr-1 -/- mice 72h after CCl4 to 
elucidate previously unrecognized antioxidant gene targets of Egr-1 (Table 2). 
Surprisingly, the expression of superoxide dismutase (SOD) 1 and 2, known gene targets 
of Egr-1, remained unchanged. However, there was significant reduction in the 
expression of other antioxidants such as glutathione peroxidase (Gpx) 2, thioredoxin 
(Txnip), sulfiredoxin (Srxn) 1, and NAD(P)H dehydrogenase, quinone 1 (Nqo1). 
Subsequent validation by real-time PCR confirmed the loss of Nqo1 mRNA and protein 
in ethanol-fed, Egr-1 -/- mice after CCl4 (Fig. 4A-B). Interestingly, examination of Nqo1 
transcript levels in isolated HSC found that wild-type mice showed a decrease in Nqo1 
mRNA over the course of plate-induced activation while Egr-1 -/- mice had significantly 
less Nqo1 that did not change over time in culture (Fig. 4C). Together, these data indicate 
that Egr-1 regulates Nqo1, whether through a direct or indirect relationship, however, 
remains unclear.  
Egr-1 recognizes and binds DNA at a GC-rich consensus sequence identified as 
5’-GCGTGGGCG-3’ [30]. In silico analysis revealed a potential Egr-1 DNA binding site 
in the Nqo1 promoter, less than 1Kb upstream of the transcriptional start site (TSS) (Fig. 
5A). To more closely explore the relationship between Egr-1 and the Nqo1 promoter, 
chromatin immunoprecipitation (ChIP) was performed in liver samples at baseline and 2h 
following CCl4 administration—when Egr-1 induction is the highest (Fig. 5B). Analysis 
by real-time PCR confirmed that Egr-1 was absent from the Nqo1 promoter at baseline 
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when Egr-1 was not expressed, and at peak Egr-1 induction there was indeed an 
association of Egr-1 to the promoter region. These data demonstrate direct DNA binding 
of Egr-1 to the Nqo1 promoter, where the loss of Egr-1 results in reduced expression of 





Table 2. An SA Biosciences Oxidant Stress, Antioxidant Defense Pathway array 
elucidated reduced antioxidants in ethanol-fed, CCl4-exposed Egr-1 -/- mice. Boxes 
in yellow indicate known antioxidant gene targets of Egr-1; fold changes show no change 
in expression. Boxes in red indicate previously unidentified gene targets of Egr-1 that are 











Layout 1 2 3 4 5 6 7 8 9 10 11 12 
A 
Gpx8 Aass Als2 Apc Apoe Aqr Atr Cat Ccs Xirp1 Ctsb Cyba 
2.06 2 -2 2 1.01 2.05 -1.98 -1.99 1 1.01 1.01 1 
B 
Cygb Dnm2 Duox1 Ehd2 Epx Ercc2 Ercc6 Fancc Fmo2 Gab1 Gpx1 Gpx2 
2 2.01 1.01 -1.01 1.01 1.01 2.01 1.01 2.03 -1 1.02 -7.98 
C 
Gpx3 Gpx4 Gpx5 Gpx6 Gpx7 Gsr Gstk1 Hbq1a Idh1 Ift172 Il19 Il22 
2.02 -1 1.01 2.04 1.01 -1.98 1 1.01 -1.98 1.01 1.01 1.01 
D 
Kif9 Lpo Mb Mpo Mpp4 Ncf2 Ngb Nos2 Nox1 Nox4 Noxa1 Noxo1 
1.01 1.01 1.01 -1.06 1.01 2.05 1.01 1.03 1.01 2.01 2.05 2.03 
E 
Nqo1 Nudt15 Nxn Park7 Ppp1r15b Prdx1 Prdx2 Prdx3 Prdx4 Prdx5 Prdx6 
Prdx6-
ps1 
-3.97 1 4.14 2.02 1.01 1.01 2.04 -1 1.01 2.02 2.03 1.01 
F 
Prnp Psmb5 Ptgs1 Ptgs2 Rag2 Recql4 Scd1 Serpinb1b Slc38a1 Slc41a3 Sod1 Sod2 
2.01 1.01 1 1.01 1.01 1 -3.96 -1.98 -2.01 2.02 1.01 -1 
G 
Sod3 Srxn1 Tmod1 Tpo Txnip Txnrd1 Txnrd2 Txnrd3 Ucp3 Vim Xpa Zmynd17 
1.02 -3.96 1.01 1.01 -32.84 -1.97 1.02 2.02 1.01 2.03 1.01 1 
Table 2: Oxidant Stress and Anti-Oxidant Pathway Array (wt vs Egr-1-/- after EtOH & CCl4 
exposure) 

















Figure 4. Egr-1 deficiency results in loss of Nqo1 mRNA and protein in whole liver 
and HSC. (A) Real-time PCR analysis on whole liver 48 and 72h after CCl4 shows there 
is a loss of Nqo1 induction, which is worsened with ethanol feeding. (B) Western blot 
analysis of Nqo1 protein levels. (C) HSC isolated from wild-type mice show a slight 
decrease in Nqo1 mRNA over the course of plate-induced activation (p = 0.06 at 72h).  









Figure 5. Chromatin immunoprecipitation confirms association between Egr-1 and 
the Nqo1 promoter. (A) In silico analysis of the Nqo1 promoter identified a putative 
Egr-1 binding site (in yellow) less than 1Kb upstream of the transcription start site. 
Forward and reverse ChIP primers are highlighted in blue and the TATA box is 
highlighted red. (B) Preliminary work in CCl4-exposed, chow-fed mice showed an 
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     AAAGGGTTCCCCGGGAGCAAGGGAGTGAGAGAGAATTTGA!
-220 GGATATGGGGACATATTGAATAAATTCATCTGCTCCCTGT!
     CCCAAGACCTCCTGGGTACAAAATGGAAATTTCCAACAGA!
-300 ATTTTTCGAGCTTCGTGGGACCTGCCTACATAATCAGCCT!
     GTGTAGATTAGTCCTCACTCAGCCGTGGGAAGTCACCTTT!
-380 GCACGCTAGGGGAAGGGTGGGGCAGCAAAACGGATGGGCT!
     CAAATTTTGCCGACTCACTGTGACTCTAGACTGAAAGTTC!
-460 AGAGAGACTTGTCCTCGTGTGAAATGAATTCGTGCTGCGT!
     TCTGCTCTTAGAAACTGCAAAAACTGCTCCCTGGGTATAC!
-540 ACACTTGGGTCTCCTCAACTTTGCCCCCGGTGACCAGGTA!
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Oxidative damage after ethanol feeding and CCl4 is independent of Egr-1-mediated 
reduction in Nqo1. Reactive oxygen species formed from CYP2E1-mediated byproducts 
of CCl4 metabolism damage hepatocytes and are eventually released into the extracellular 
matrix where they can injure surrounding hepatocytes and stimulate the activation of 
HSC [31]. We hypothesized that Egr-1 deficiency would reduce antioxidant defense 
necessary to attenuate oxidative damage in parenchymal cells, and accelerate the 
appearance of fibrosis markers. Nqo1 is commonly recognized for its antioxidant 
capabilities. Known to reduce quinones to hydroquinones, Nqo1 bypasses the production 
of free radicals that result from one-electron reduction processes by utilizing a two-
electron reduction pathway. Reportedly, this flavoprotein is also involved in scavenging 
and reducing superoxide [32]. Since there is no quinone generation during the 
metabolism of CCl4, we took multiple approaches to measure the severity of oxidative 
stress in Egr-1 -/- mice compared to wild-type (Fig. 6).  
First, immunohistochemistry of 4-hydroxynonenal (4-HNE) was performed to 
measure levels of lipid peroxidation after CCl4 exposure. Lipid peroxidation, or the 
oxidative degradation of lipids, is a crucial step in the pathogensis of many diseases and it 
is commonly quantified by the presence of peroxidation byproducts—reactive aldehydes 
such as 4-HNE and malondialdehyde (MDA) [33]. Contrary to our hypothesis, Figures 
6A and B show no difference in histological representation or quantification of 4-HNE 
immunological staining 12h after CCl4, a time point when 4-HNE adducts remain 
detectable.  
Second, we measured glutathione (GSH) levels in a glutathione depletion assay 
(Fig. 6C). Redox reactions that convert GSH to its oxidized state, glutathione disulphide 
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(GSSG), reduce organic peroxides formed by oxidative stress and play an important role 
in cellular detoxification [34]. During this process in which GSH is depleted from the 
cell, the ratio of GSSG/GSH can be used as an indicator of oxidative damage and 
recovery. Therefore, an increased GSSG/GSH ratio is considered indicative of increased 
oxidative stress. However, over time GSSG is converted back to GSH by glutathione 
reductase, which is constitutively active and inducible by oxidative stress. Unexpectedly, 
pair-fed, Egr-1 -/- mice showed an increased GSSG/GSH ratio, and thus lower levels of 
GSH at baseline. Moreover, ethanol appeared to decrease GSH at baseline in wild-type 
animals alone. Even so, GSSG/GSH ratios decreased and GSH levels recovered similarly 
in all groups 12h following CCl4, negating the idea that the glutathione system is more 
overwhelmed in Egr-1 -/- mice.  
Third, we used a Total Antioxidant Capacity assay kit to directly measure the 
antioxidant capacity of wild-type and Egr-1 -/- mouse livers 12h after CCl4 (Fig. 6D). 
Typically, antioxidants eliminate free radicals through hydrogen atom transfer or single 
electron transfer mechanisms. This assay quantified the ability of cellular antioxidant 
enzymes to transfer one electron to reduce copper (II) to copper (I). Earlier time points 
(1, 2, and 6h) in wild-type mice showed a slight reduction in total antioxidant capacity up 
to 6h following CCl4 that recovered to baseline levels by 12h (data not shown), consistent 
with patterns of lipid peroxidation. Comparatively, by 12h post CCl4, not only were 
copper-reducing equivalents recovered to baseline in Egr-1 -/- mice, but also there was 
no difference between diets or genotypes. Collectively, these data imply that the loss of 
Nqo1 via Egr-1 deficiency neither increases oxidative stress nor reduces cellular 
antioxidant defense in Egr-1 -/- mice ensuing CCl4 administration.  























Figure 6. Reduced Nqo1 does not affect oxidative stress, cellular glutathione or total 
antioxidant capacity after CCl4. Twelve hours post CCl4, lipid peroxidation and 
glutathione levels were measured by immunohistochemistry of 4-HNE and a glutathione 
depletion assay, respectively (A-C).  Total antioxidant capacity was assayed with the use 
of a kit that quantifies the capacity of antioxidant enzymes to reduce copper (II) to copper 
(I) (D).  
 
 
Loss of Nqo1 does not affect mitotic spindle assembly. In addition to the role Nqo1 
plays in attenuating oxidative damage, it is also associated with stabilizing microtubules 
of the mitotic spindle during mitosis [35, 36]. In particular, a role for Nqo1 in influencing 
microtubule polymerization was confirmed using inhibition studies in xenopus egg 
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in mitotic spindles of different human cell lines [36]. Consequently, since the above data 
demonstrated no change in oxidative stress with the loss of Nqo1, we ruled out Nqo1’s 
antioxidant capacity as contributing to the reduced fibrogensis seen in wild-type mice 
compared to Egr-1 -/- mice. We subsequently explored the hypothesis that reduced Nqo1 
leads to microtubule instability and abnormal mitotic spindle formation (e.g. tripolar 
spindles) resulting in apoptotic hepatocytes—stimuli for HSC activation. Quantification 
of mitotic figures was performed on hematoxylin and eosin stained histology sections 
from livers at baseline, 48 and 72h post CCl4 (Fig. 7). Liver regeneration and entrance 
into the cell cycle did not begin until 48h after CCl4 in wild-type mice, whereas Egr-1 -/- 
mice appeared to experience delayed mitosis, which was further inhibited by ethanol 
feeding (Fig. 7B). While Egr-1 -/- mice entered mitosis by 72h following CCl4, they 
showed a lower number of cells in the mitotic phase of the cell cycle compared to wild-
type, and the number of abnormal mitotic figures did not differ between genotypes (Fig. 
7B-C).  
The importance of Egr-1 in the regulation of entry into the cell cycle and mitotic 
progression has previously been reported in studies where Egr-1 null mice exhibited 
impaired liver regeneration after partial hepatectomy and acute CCl4 exposure [21, 37]. 
Therefore, the reduced presence of mitotic figures in Egr-1 -/- mice seen here is not 
unexpected. However, these data suggest that loss of Nqo1 at the mitotic spindle in Egr-1 
-/- mice does not affect the stability of the mitotic spindle nor the cell’s ability to divide.  
 





Figure 7. Loss of Nqo1 does not affect mitotic spindle assembly. (A) Hematoxylin and 
eosin-stained sections of wild-type and Egr-1 -/- liver at baseline, 48 and 72h post CCl4. 
At 48h, examples of mitotic figures during metaphase and anaphase are designated in 
insets. At 72h, examples of abnormal mitotic spindles (e.g. tripolar spindles) are pictured 
in insets. (B) Quantification of mitotic figures averaged per field of view (f.o.v). (C) 
Graphical representation of abnormal or tripolar spindles per f.ov.72h after CCl4. 
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Ethanol feeding inhibits the recovery of cellular NAD+/NADH ratios after CCl4 
independent of Egr-1. Looking beyond Nqo1’s ability to eliminate ROS and stabilize 
microtubules, it also plays a role in the modulation of reduced to oxidized nicotinamide 
nucleotide ratios. Not only does Nqo1 require FAD as a cofactor for its enzymatic 
activity, but it also contains a NAD(P)H binding site. During times of cell injury as in 
ethanol feeding or succeeding CCl4 exposure, levels of NADH rise in the cell as NAD+ is 
used as a coenzyme in metabolism [38]. NADH can then bind Nqo1, donating an electron 
to FAD and allowing quinone substrates to bind the reduced FAD-enzyme complex for 
detoxification [39]. During this process, NADH is oxidized to NAD+, helping to restore 
the cellular redox state to a nicotinamide nucleotide ratio in favor of NAD+. Similar to 
results shown by Yuki et. al [38], CCl4 significantly reduced cellular NAD+/NADH 
ratios 48h after treatment, favoring accumulation of NADH (Fig. 8). While there was 
partial recovery of NAD+ by 72h in pair-fed animals, ethanol feeding resulted in 
inhibition of reoxidation of NADH in both genotypes. However, since these ratios did not 
differ between genotypes, we concluded that inhibition of NADH reoxidation in Egr-1 
deficient mice does not contribute to the enhanced fibrogenic changes seen in these 
























Figure 8. Ethanol feeding inhibits the recovery of cellular NAD+/NADH ratios after 
CCl4 independent of Egr-1. NADH decreases during cell injury and is necessary for 
maintaining cell homeostasis. An NAD+/NADH quantification colorimetric assay was 
performed on wild-type and Egr-1 -/- livers 48 and 72h post CCl4.  
 
 
β-Lapachone-mediated increases in Nqo1 activity inhibit the induction of early 
markers of fibrosis in wild-type mice after CCl4. β-Lapachone (βL), isolated from the 
bark of the lapacho tree, has been identified as a potent enzymatic activator of Nqo1 [40]. 
Recently, researchers have taken advantage of Nqo1 overexpression in some cancers, 
using Nqo1-mediated bioactivation of βL and other quinone-derived chemotherapeutic 
agents to exert cytotoxic effects on cells in cancer treatment [41]. Since increased NADH 
oxidation by βL has previously been shown to ameliorate metabolic syndrome and 
attenuate cisplatin-induced renal injury [42, 43], pharmacological activation of Nqo1 was 
used to better understand the importance of Nqo1 induction in the protection against 
fibrogenic changes in the liver after ethanol feeding and CCl4 exposure. We administered 
βL to increase basal levels of Nqo1 activity in wild-type mice to attenuate the appearance 
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of early markers of hepatic fibrosis. Seventy-two hours after treatment with CCl4, Nqo1 
activity was increased (Fig. 9A), and CCl4-induced elevation of plasma ALT activity was 
reduced in βL-treated animals compared to control (Fig. 9B). Additionally, HSC 
activation, as measured by Col1a1 and αSMA transcript levels, was decreased in βL-
treated mice (Fig. 9C-D). These results suggest that stimulation of Nqo1 activity protects 
























Figure 9. β-Lapachone-mediated induction of Nqo1 activity reduces the expression 
of early markers of fibrosis after CCl4.	  (A) Nqo1 activity was assayed and reported as 
the amount of 2,6-dichlorophenolindophenol (DCPIP, substrate) reduced over time. (B) 
Plasma ALT activity was determined to assess liver injury 72h post CCl4 in wild-type 
mice, while real-time PCR analysis was performed to measure quantities of (C) Col1a1 
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Discussion 
Egr-1 has been extensively characterized in the regulation of genes critical to 
wound healing and is implicated in fibrosis [14]. While models of bleomycin-induced 
dermal and lung fibrosis exhibit attenuated disease in the absence of Egr-1 [15], models 
of cholestatic liver injury and hepatic fibrosis demonstrate increased injury with the loss 
of Egr-1 [17, 19]. Consistent with these studies in the liver, we demonstrated that Egr-1 
deficiency protected against fibrogenic changes in the liver associated with moderate 
ethanol feeding and CCl4 exposure, independent of changes in liver injury or CYP2E1-
mediated bioactivation of CCl4.  
Multiple studies suggest that the oxidation of ethanol leads to an increase in Egr-1 
expression [7, 44, 45]. Analogous to such studies in mice subjected to chronic ethanol 
feeding, peak induction of Egr-1 mRNA was enhanced in ethanol-fed mice compared to 
pair-fed mice 2h following CCl4 administration (data not shown). This induction may be 
important for the initial inflammatory response following injury, but we suspect that the 
secondary induction in Egr-1 transcript levels seen in mice 48h post CCl4 is more critical 
for the wound healing response accessory to inflammation, regulating extracellular 
matrix remodeling in a tightly controlled manner and reducing fibrosis. Therefore, the 
ethanol-dependent reduction in Egr-1 mRNA in mice at 48h may provide an additional 
explanation for the enhanced expression of early markers of fibrosis displayed in ethanol-
fed animals in ours and other studies [20]. Interestingly, these same models have 
demonstrated that Egr-1 is required for the development of ethanol-induced steatosis 
through enhanced LPS sensitivity in Kuppfer cells and successive upregulation of TNFα 
[16]; however, we showed that the loss of Egr-1 delayed recovery of the liver from CCl4-
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induced steatosis, and ethanol feeding worsened this effect. While TNFα activation plays 
a role in the development of hepatic steatosis, there is considerable redundancy in the 
regulation of lipid metabolism, and so it is possible that the heightened steatosis in Egr-1 
-/- mice seen 72h after CCl4 is independent of TNFα expression.  
The rapid and transient induction of Egr-1 by oxidative stress in the progression 
of a number of diseases led us to hypothesize that Egr-1 may regulate antioxidants crucial 
for the detoxification of CCl4-induced liver injury. While research has shown that Egr-1-
dependent gene expression of SOD1 appeared to play a role in the control of oxidant 
stress in atherosclerotic lesions [46], we found no change in expression of SOD 1 or 2 in 
Egr-1 -/- mice 72h after ethanol feeding and CCl4. However, an oxidant stress, 
antioxidant defense pathway array and sequential analysis by real-time PCR and Western 
blot elucidated the antioxidant Nqo1 as a potential target of Egr-1 and mediator of 
cellular protection from oxidative damage. Expressed at low levels under basal 
conditions, Nqo1 induction is thought to be more important during periods of hepatic 
injury and oxidative stress [47]. For example, Nqo1 protein and activity was markedly 
elevated in mouse liver following bile duct ligation as well as following exposure to 
hepatoxicants such as acetaminophen (APAP) and CCl4 [48]. Unexpectedly, despite 
increased levels of Nqo1 mRNA and protein, abrogated by Egr-1 deficiency and ethanol 
feeding, analysis of oxidative stress and cellular antioxidant capacity illustrated no 
differences between diets and genotypes after CCl4 exposure. Surprisingly, although we 
demonstrated that the loss of Nqo1 via Egr-1 deficiency did not affect NADH reoxidation 
72h after CCl4, we showed that β-Lapachone administration attenuated liver injury and 
fibrogenic changes induced by CCl4 through activation of Nqo1 activity. Together, these 
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data suggest that accumulation of NADH and loss of antioxidant defense does not 
contribute to enhanced fibrogenesis in Egr-1 deficient mice. However, the attenuation of 
liver injury by βL does not rule out a protective role for Nqo1 in hepatic fibrosis.  
βL, a naturally occurring compound that has been used medicinally for years, has 
several known modes of action through which it can trigger apoptosis in Nqo1- 
overexpressing cancer cells. Originally discovered as an inhibitor of DNA topoisomerase 
I, βL toxicity is associated with single and double strand DNA breaks as well as 
inhibition of DNA replication [49]. Whereas quinone metabolism by Nqo1 normally 
produces stable hydroquinone species that are conjugated for excretion, metabolism of βL 
by Nqo1 generates a reactive, unstable hydroquinone that is oxidized to a semiquinone 
[50]. Semiquinones are free radicals that stimulate redox cycling and lead to production 
of ROS such as superoxide and hydrogen peroxide, which can damage the cell. 
Reduction of βL by Nqo1 additionally leads to futile cycling between its quinone and 
hydroquinone forms causing depletion of cytosolic NADH and subsequent activation of 
calpain-mediated cell death. While similar studies in which βL attenuated cisplatin-
induced renal injury showed suppression of critical mediators of inflammation and ROS 
by NAD-dependent activation of Sirt1 [43], we showed that βL abated CCl4-induced liver 
injury independent of increased intracellular NAD+. We demonstrated that treatment 
with βL did in fact enhance Nqo1 activity, and transcript levels of Col1a1 and αSMA, 
expressed by activated HSC, were decreased in βL-treated mice compared to vehicle 
treated mice. However, we suspect that the reduction in injury and markers of 
fibrogenesis is more likely due to the activation of apoptotic signaling pathways in 
hepatic stellate cells. While stellate cells may undergo senescence or revert back to a 
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quiescent phenotype after activation, apoptosis is also prominent in stellate cells and is an 
important mechanism for the regression of fibrosis [51]. Though previous studies have 
shown the stimulation of apoptosis in HSC to be an attractive anti-fibrotic therapeutic 
approach [52], further studies should be done to investigate the mechanisms by which βL 
inhibits CCl4-induced liver injury.  
Additionally, following these studies, RNA sequencing and validation with real-
time PCR identified reduction in several carboxylesterase (Ces) 1 isoforms (Table 3, Fig. 
10A), identifying an alternative method of lipogenic dysregulation after CCl4, 
independent of NADH accumulation. Recent studies have reported that global Ces1 -/- 
mice develop hepatic steatosis and that activation of Ces1 in the liver lowered hepatic 
triglyceride levels and improved glucose tolerance in obese mice through previously 
unrecognized triglyceride hydrolase activity [53]. Reduced triglyceride hydrolase activity 
due to polymorphisms in other triglyceride lipases such as adipose triglyercide lipase 
(ATGL), patatin-like phospholipase domain-containing (PNPLA) 2 and 3 predisposes 
patients towards the full spectrum of liver damage associated with fatty liver [54, 55]. 
Consistently, we found complete inhibition of PNPLA3 mRNA in Egr-1 -/- mice 
compared to wild-type 48 and 72h after CCl4 (Fig. 10B). This evidence of perturbed lipid 
homeostatic mechanisms provides an additional explanation for increased steatosis seen 
in ethanol-fed, CCl4-exposed Egr-1 -/- mice. Furthermore, additional RNA sequencing 
data highlighted increases in profibrotic mediators as well as loss of glutathione-s-
transfersases in these animals (Table 3). Collectively, these pathways strongly imply a 
protective role for Egr-1 in the development of hepatic fibrosis following ethanol-
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accelerated, CCl4-induced liver injury that would be of great interest to explore in future 
studies.  
Although it has been reported that Egr-1 mRNA expression is heightened in livers 
of patients with chronic cholestasis [56], the status of Egr-1 in patients with ALD remains 
unclear. Not only would understanding the expression of Egr-1 in human fibrosis be 
essential, but further studies would also be required to understand the functions of other 
Egr-1-expressing cell types in the development of liver fibrosis. Consistent with CCl4-
mediated increases in Nqo1 mRNA and protein we saw in whole liver, initial studies in 
APAP-induced liver injury and primary biliary cirrhosis show that Nqo1 expression and 
activity are also increased in hepatocytes of these two types of human liver disease [47]. 
Interestingly, while we showed that expression of Nqo1 was increased by CCl4 exposure 
in whole liver, which was reduced by Egr-1 deficiency and ethanol feeding, Nqo1 mRNA 
decreased during plate-induced activation of wild-type HSC and the loss of Egr-1 
robustly enhanced this effect. We postulate that because Nqo1 is a negative regulator of 
fibrosis, its downregulation is critical for the activation of HSC in fibrogenesis. 
Therefore, it will be very important to investigate and consider Egr-1 function in the 
many cell types involved in the development of hepatic fibrosis for more directly targeted 
therapeutic treatments.  
In future studies, we would like to corroborate our chromatin 
immunoprecipitation findings with a luciferase reporter assay and electrophoretic 
mobility shift assay. Comparative to pharmacological activation of Nqo1, we would also 
like to pharmacologically inhibit Nqo1 with dicoumarol or ES936 to establish that the 
attenuation of hepatic fibrosis by Egr-1 is Nqo1-dependent [36, 57]. Similarly, the use of 
	   	   	   	  38	  
Nqo1 -/- mice could affirm this hypothesis. Importantly, in addition to the functions of 
Nqo1 that we have investigated throughout this study, Nqo1 also regulates protein 
degradation through interaction with the 20S proteasome [57]. Therefore, to understand 
the mechanisms by which Nqo1 contributes to protection from fibrosis, we will 
investigate how Nqo1’s association with the 20S proteasome may be a contributing 
factor. Additionally, further validation of results obtained from RNA sequencing may 
elucidate other pathways essential to the attenuation of liver fibrosis by Egr-1. 
Futhermore, determining the function of other Egr-1-expressing cell types in liver disease 
progression as well as the status of Egr-1 in primary human hepatocytes of ALD patients 
will help us better understand the role of Egr-1 in human liver disease.  
In summary, ethanol feeding reduces Egr-1 during fibrogenesis in response to 
CCl4-induced liver injury in wild-type mice. Independent of enhanced peak liver injury 
and bioactivation of CCl4, Egr-1 deficient mice had significantly increased levels of 
αSMA mRNA and protein as well as increased expression of type I collagen compared to 
wild-type mice. Ethanol feeding potentiated this effect. Of interest, the increase in early 
fibrosis markers in Egr-1 null mice was accompanied by an increase in hepatic 
triglycerides 72h after CCl4 and by inhibition of Nqo1 induction, which was exacerbated 
by ethanol feeding. Chromatin immunoprecipitation confirmed direct binding of Egr-1 to 
the Nqo1 promoter, introducing Nqo1 as a novel gene target of Egr-1. Although reduction 
of Nqo1 did not affect oxidative damage, mitotic spindle assembly, or NADH oxidation 
in Egr-1 -/- mice compared to wild-type, attenuation of CCl4-mediated liver injury and 
fibrogenic changes by β-Lapachone suggests a potential role for Nqo1 in protection from 
hepatic fibrosis. However, a better understanding of the disparate contributions of Egr-1 
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in different models of fibrosis as well as the mechanisms by which Nqo1 exerts inhibitory 
effects on CCl4-induced liver injury is crucial for development of therapeutic anti-fibrotic 
interventions targeting the two. 
 
 
Table 3. A Next Gen Sequencing pilot project identified 3 interralated networks 
whose dysregulation is associated with an enhanced fibrogenic phenotype in 
ethanol-fed, Egr-1 deficient mice after CCl4 exposure. Fold changes indicated show 
differences in expression between CCl4-exposed, wild-type and Egr-1 -/- mice.  
 
 
Figure 10. Egr-1 deficiency limits hepatic lipid-regulatory mRNA induction after 
CCl4 exposure; ethanol-feeding further suppresses these genes. Hepatic accumulation 
of (A) Ces1d and (B) PNPLA3 transcripts was determined by real-time PCR 48 and 72h 
after CCl4, validating RNAseq data. 









Ctgf% 3.8$ Gsta1% %12.2$ Ces1b% %11.1$
Mmp9% 3.7$ Gsta2% %30.6$ Ces1d% %28.08$
Col2A1% 4.1$ Nqo1% %12.5$ Ces1e% %8.8$
Lox% 3.3$ Ces2a% %48.4$
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